Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Nieuwlaat, R.
Right arrow Articles by Crijns, H. J.G.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Nieuwlaat, R.
Right arrow Articles by Crijns, H. J.G.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2007. For permissions please email: journals.permissions@oxfordjournals.org

Atrial fibrillation in the ‘real world’: undecided issues

Robby Nieuwlaat1,*, Luc W. Eurlings1, Alessandro Capucci2 and Harry J.G.M. Crijns1

1 Department of Cardiology, University Hospital Maastricht, Maastricht, The Netherlands
2 Department of Cardiology, Guglielmo da Saliceto Hospital, Piacenza, Italy

* Corresponding author. Tel: +31 43 3875093; fax: +31 43 3875104. E-mail address: h.crijns{at}cardio.azm.nl

Atrial fibrillation (AF) is an obstinate and widespread arrhythmia with multiple presentations and potential for hazardous consequences. Although our knowledge of AF is advancing, the onset and progression of AF and the interaction with its many associated diseases is not fully understood. Also, management recommendations on evidence based issues are frequently ignored for a wide range of reasons. The following developments are expected to improve efficacy, safety, and guideline adherence regarding the management of AF: earlier detection of AF, improved understanding and management of its associated diseases, adequate rate-control targets, more effective and safer rhythm control measures, an easy-to-use risk stratification scheme incorporating both risk factors for stroke and major bleeding to tailor antithrombotic treatment, and anticoagulation drugs not requiring monitoring of the international normalized ratio. Translational researchers, clinical trialists, and epidemiologists should complement each other to fulfil the current needs in the management of AF and to monitor whether there are solutions for existing ‘undecided issues’ and new ones are developing.

Key Words: Atrial fibrillation • Management • Practice • Guidelines


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.